AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20040526
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 4 weeks, followed by 125 mg twice daily for 12 weeks
Trial: 11901542
Drug: Peptide vaccines
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccines derived from tumor antigens
Trial: 10352750
Drug: Octreotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide treatment (daily dosage of 470 +/- 160 micrograms for 16.5 +/- 10 weeks)
Trial: 10352750
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Octreotide treatment)
Trial: 8619354
Drug: Iobitridol 300
RxNorm normalized name: iobitridol 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iobitridol 300 mg I/ml
Trial: 8619354
Drug: Iopromide 300
RxNorm normalized name: IOPROMIDE 300mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide 300 mg I/ml
Trial: 1953212
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg once daily at bedtime (n = 15)
Trial: 1953212
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg twice daily (n = 11)
Trial: 30186865
Drug: Ultrasonic implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic implant site preparation (UISP)
Trial: 27278250
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment for psychotic disorders (18 months of therapy including 60 hours of group therapy and 15 hours of individual therapy)
Trial: 24488700
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neuroendocrine factors
Trial: 19453582
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + ketamine 0.5 mg.kg(‐1)
Trial: 19453582
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + same volume of %0.9 NaCl
Trial: 15265969
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (four cycles of doxorubicin 75 mg/m2, followed by a single cycle of intermediate-dose cyclophosphamide 4000 mg/m2 supported by filgrastim 300 microg/day for up to 10 days, followed by high-dose cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2)
Trial: 15265969
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (four cycles of doxorubicin 75 mg/m2 followed by eight cycles of CMF: cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and 5-fluorouracil 600 mg/m2)
Trial: 2486586
Drug: Standard morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard morphine parenteral analgesia (Group 1)
Trial: 1086422
Drug: Leucovorin-tablets
RxNorm normalized name: leucovorin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin-tablets
Trial: 30526692
Drug: 35 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 µg vitamin D3/d
Trial: 30526692
Drug: >85 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >85 µg vitamin D3/d
Trial: 30526692
Drug: 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg vitamin D3/d
Trial: 30526692
Drug: 85 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85 µg vitamin D3/d
Trial: 23848107
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (10 mg/day for 6 months)
Trial: 8498867
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of varicocele (26 patients)
Trial: 8498867
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (41 patients)
Trial: 8498867
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (surgical, sclerosation, embolization)
Trial: 27250601
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l polyethylene glycol (PEG) in a single dose
Trial: 27250601
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l polyethylene glycol (PEG) split into 3 + 1 l
Trial: 27250601
Drug: PEG +
RxNorm normalized name: Polyethylene glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG + ascorbic acid (PEGA) split into 1 + 1 l or 2 l
Trial: 19322744
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg/day (n=23)
Trial: 12620950
Drug: Continuous intra‐articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intra‐articular infusion with 0.2% ropivacaine at 10 mL/hr for 48 hours
Trial: 12620950
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene block with 0.2% ropivacaine at 10 mL/hr for 48 hours
Trial: 10946875
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum levels of insulin-like growth factor I (IGF-I)
Trial: 10946875
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor binding protein-3 (IGFBP-3)
Trial: 8817135
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg every 6 hours postoperatively)
Trial: 8817135
Drug: Diltiazem (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.1 mg/kg per hour i.v.)
Trial: 1486965
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline and ketotifen (TK; T 300 mg+K 1 mg b.i.d.)
Trial: 6363488
Drug: Atropine 2.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 2.08 mg
Trial: 3764397
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg i.m.)
Trial: 23706700
Drug: Macular leakage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macular leakage (ML) presence
Trial: 20939644
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .100%
Trial: 20939644
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .075%
Trial: 20939644
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .050%
Trial: 20939644
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .000%
Trial: 16790517
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² on day 1 and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks (group A)
Trial: 16790517
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and pegylated liposomal doxorubicin 40 mg/m² on day 1 every 4 weeks (group B)
Trial: 15035763
Drug: Albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol by nebulizer every 20 minutes up to 2 hours
Trial: 15035763
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler with spacer every 20 minutes up to 2 hours
Trial: 11099870
Drug: Transdermal E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal E(2) and oral medroxyprogesterone acetate
Trial: 11099870
Drug: Oral cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclic association of oestradiol valerate and cyproterone acetate
Trial: 18480626
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg lidocaine suppository 2 h before biopsy
Trial: 18480626
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg lidocaine suppository 1 h before biopsy
Trial: 18480626
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg lidocaine suppository 2 h before biopsy
Trial: 18480626
Drug: Periprostatic infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic infiltration of 5 ml 2% lidocaine
Trial: 12859158
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg for 5 weeks, then 100 mg for 5 weeks)
Trial: 12859158
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg after 5 weeks)
Trial: 8611830
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of aminoglycosides
Trial: 8611830
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of aminoglycosides
Trial: 27718369
Drug: Ketamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (single infusion of sub-anesthetic dose)
Trial: 26202488
Drug: Denosumab treatment
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab treatment for 8 years (long-term group)
Trial: 26202488
Drug: Denosumab treatment
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab treatment for 5 years (cross-over group)
Trial: 26202488
Drug: Denosumab treatment
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab treatment (both groups)
Trial: 23176888
Drug: Early interventional
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early interventional treatment with mometasone furoate nasal spray (EIT group)
Trial: 23176888
Drug: Postonset treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postonset treatment with mometasone furoate nasal spray (POT group)
Trial: 25876224
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (placebo group)
Trial: 17080503
Drug: Method applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Method applied to bioequivalence study of two furosemide-containing formulations
Trial: 11070330
Drug: LHRH (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH (400 microg acute administration)
Trial: 9041232
Drug: Zileuton (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (600 mg qid)
Trial: 9041232
Drug: Mesalazine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (400 mg qid)
Trial: 8178840
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg daily)
Trial: 8178840
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg daily)
Trial: 8178840
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg for 14 days per 28-day cycle)
Trial: 8178840
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (10.0 mg for 14 days per 28-day cycle)
Trial: 8178840
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) alone
Trial: 3228824
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg slow‐release isosorbide‐5‐mononitrate (ISMN SR) once daily
Trial: 3228824
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine SR twice daily
Trial: 28780559
Drug: Low-energy total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy total diet replacement programme (810 kcal/d) for 8 weeks, followed by gradual food reintroduction and weekly behavioural support for 24 weeks.
Trial: 23810723
Drug: Budesonide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (3 mg twice or 3 times daily) with azathioprine (1-2 mg/kg/day)
Trial: 23810723
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg/day tapered to 10 mg/day) with azathioprine (1-2 mg/kg/day)
Trial: 23810723
Drug: Open-label budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label budesonide treatment after 6 months
Trial: 17519073
Drug: Triple-bead mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-bead mixed amphetamine salts 37.5 mg
Trial: 11464179
Drug: Micronized isotretinoin
RxNorm normalized name: Micronized ISOtretinoin 8 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized isotretinoin 0.4 mg/kg once daily without food (n = 300)
Trial: 11464179
Drug: Standard isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard isotretinoin 1.0 mg/kg per day in two divided doses with food (n = 300)
Trial: 2266236
Drug: 0.1 M
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 M hydrochloric acid infusion
Trial: 2266236
Drug: 1 M
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 M sodium bicarbonate infusion
Trial: 27883269
Drug: Standard six-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard six-dose AL treatment with milk (A)
Trial: 27883269
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of AL
Trial: 27883269
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of AL
Trial: 21901330
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) with a dose of 0.7 μg/kg/h after initial dose and effect-site concentration (ESC) of fentanyl of 2 ng/ml
Trial: 21901330
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) with ESC of fentanyl of 4 ng/ml
Trial: 9735411
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) plus standard-dose external-beam whole-brain radiation treatment (WBRT)
Trial: 26482278
Drug: Etirinotecan pegol
RxNorm normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etirinotecan pegol (145 mg/m² as a 90-min intravenous infusion every 3 weeks)
Trial: 21707533
Drug: Galantamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine treatment (subgroup analysis)
Trial: 16929307
Drug: L-DOPA (3,4-dihydroxy-L-phenylalanine)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-DOPA (3,4-dihydroxy-L-phenylalanine)
Trial: 11054514
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiotherapy (V-CHART) delivering a total dose of 55.3 Gy in 33 fractions over 17 consecutive days
Trial: 11054514
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiotherapy with mitomycin C (V-CHART+MMC) with additional administration of 20 mg/m2 MMC on day 5 of treatment
Trial: 9375429
Drug: Agents (prayers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents (prayers)
Trial: 9375429
Drug: Amount of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amount of prayer by agents
Trial: 23206974
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose administered 5 years post-vaccination
Trial: 23206974
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose administered 10 years post-vaccination
Trial: 23206974
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose administered 15 years post-vaccination
Trial: 23206974
Drug: No booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No booster dose (5, 10, or 15 years post-vaccination)
Trial: 21435876
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg idebenone (Catena®)
Trial: 18491311
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3.5 g daily)
Trial: 18491311
Drug: High oleic
RxNorm normalized name: High Oleic Sunflower Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oleic sunflower oil (3.5 g daily)
Trial: 11213546
Drug: Fentanyl (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2.0 micrograms/kg) and atropine (0.01 mg/kg) as premedication
Trial: 11213546
Drug: Remifentanil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.2 microgram/kg/min) and atropine (0.01 mg/kg) as infusion
Trial: 3881294
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Ethinylestradiol (EE) for 5 consecutive days
Trial: 3881294
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms Ethinylestradiol (EE) and 2 mg dl‐norgestrel (NG)
Trial: 29419896
Drug: Excimer lamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excimer lamp (twice weekly)
Trial: 29419896
Drug: Calcipotriol-clobetasol combination
RxNorm normalized name: calcipotriol, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol-clobetasol combination (once daily)
Trial: 29419896
Drug: Calcipotriol-clobetasol combination
RxNorm normalized name: calcipotriol, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol-clobetasol combination
Trial: 27563091
Drug: Screening mechanism
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening mechanism combining free provision of chlorine solution with household vouchers that need to be redeemed monthly.
Trial: 24858151
Drug: Single visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single visit root canal treatment
Trial: 24858151
Drug: Multi visit
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi visit root canal treatment
Trial: 20566266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pre-notification and follow-up
Trial: 18036451
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg twice per day
Trial: 15826716
Drug: Lactitol 60
RxNorm normalized name: Lactitol
DrugBank: Lactitol (DB12942)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactitol 60 g/day
Trial: 2185404
Drug: Molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (2 X 8 mg/d)
Trial: 2185404
Drug: Nifedipine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (3 X 20 mg/d) and acetylsalicylic acid (1 X 500 mg/d)
Trial: 2185404
Drug: SIN‐I (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIN‐I (0.5 mg)
Trial: 6113802
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg by intramuscular injection one hour before surgery
Trial: 31396203
Drug: Pemphigus patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemphigus patients managed with systemic medications
Trial: 28346569
Drug: 4x100,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x100,000 IU cholecalciferol every 2 weeks (treatment group)
Trial: 23523254
Drug: Intravenous tezosentan
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tezosentan (5 mg/h during surgery and up to 24 hours afterwards at 1 mg/h)